Evidence-based neoadjuvant endocrine therapy for breast cancer

Clinical Breast Cancer

Volumn 7, Issue 4, 2006, Pages 315-320

  Dienstmann, Rodrigo ^a   Bines, José ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Aromatase inhibitors; Hormonal treatment; Predictive markers; Preoperative therapy; Surrogate markers; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; GEFITINIB; KI 67 ANTIGEN; LETROZOLE; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE MARKER; DRUG POTENTIATION; ECHOGRAPHY; EVIDENCE BASED MEDICINE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAMMOGRAPHY; MASTECTOMY; METASTASIS POTENTIAL; PATIENT SELECTION; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

EID: 33750847913     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.043     Document Type: Review

References (55)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 2:104-107.
2. Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003; 14:414-420.
3. Bates T, Riley DL, Houghton J, et al. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg 1991; 78:591-594.
4. Fennessy M, Bates T, MacRae K, et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 2004; 91:699-704.
5. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from the National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003; 21:4165-4174.
6. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project protocol B-18. J Natl Cancer Inst 2001; 30:96-102.
7. Colleoni M, Zahrieh D, Gelber RD, et al. Preoperative systemic treatment: prediction of responsiveness. Breast 2003; 12:538-542.
8. Buzdar AU, Valero V, Theriault RL, et al. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 2003; 82(suppl 1):s69 (Abstract #302).
9. Untch M, Kahlert V, Moebus C, et al. Negative steroid receptors are a good predictor for response to preoperative chemotherapy in breast cancer - results of a randomized trial. Proc Am Soc Clin Oncol 2003; 22:9 (Abstract #35).
10. Cheung KL, Howell A, Robertson JFR. Preoperative endocrine therapy for breast cancer. Endocr Relat Cancer 2000; 7:131-141.
11. Preece PE, Wood RA, Nackie CR, et al. Tamoxifen as initial sole treatment of localized breast cancer in elderly women: a pilot study. Br Med J 1982; 284:869-870.
12. Hellberg A, Lundgren B, Norin T, et al. Treatment of early localized breast cancer in elderly patients by tamoxifen. Br J Radiol 1982; 55:511-515.
13. Bradbeer JW, Kyngdon J. Primary treatment of breast cancer in elderly women with tamoxifen. Clin Oncol 1983; 9:31-34.
14. Allan SG, Rodger A, Smyth JF, et al. Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J 1985; 290:358.
15. Campbell FC, Morgan DA, Bishop HM, et al. The management of locally advanced carcinoma of the breast by Novaldex (tamoxifen): a pilot study. Clin Oncol 1984; 10: 111-115.
16. Margolese RG, Foster RS. Tamoxifen as an alternative to surgical resection for selected geriatric patients with primary breast cancer. Arch Surg 1989; 124:548-550.
17. Akhtar SS, Allan SE, Rodger A, et al. A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol 1991; 17:30-35.
18. Foudraine NA, Verhoef LCG, Burghouts JT. Tamoxifen as sole therapy for primary breast cancer in the elderly patient. Lancet 1992; 2:840-842.
19. Gaskell DJ, Hawkins RA, de Carteret S, et al. Indications for primary tamoxifen therapy in elderly women with breast cancer. Br J Surg 1992; 79:1317-1320.
20. Bergman L, van Dongen JA, van Ooien B, et al. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat 1995; 34:77-83.
21. Ciatto S, Cirillo A, Confortini M, et al. Tamoxifen as primary treatment of breast cancer in elderly patients. Neoplasma 1996; 43:43-45.
22. Dixon JM, Love CDB, Renshaw L, et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 1999; 6:227-230.
23. Miller WR, Dixon JM. Endocrine and clinical end points of exemestane as neoadjuvant therapy. Cancer Control 2002; 9(suppl 2):9-15.
24. Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000; 6:2229-2235.
25. Tubiana-Hulin M, Spyratos F, Becette V, et al. Phase II study of neoadjuvant exemestane in postmenopausal patients with operable breast cancer. Breast Cancer Res Treat 2003; 82(suppl 1):s443 (Abstract #443).
26. Krainick U, Astner A, Jonat W, et al. Phase II study to define the safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer - final results of the German Neoadjuvant Aromasin Initiative (GENARI). Breast Cancer Res Treat 2003; 82(suppl 1):s55 (Abstract #239).
27. Dixon JM, Jackson J, Renshaw L, et al. Neoadjuvant letrozole: the Edinburgh experience. Breast Cancer Res Treat 2002; 76(suppl 1):s75 (Abstract #264).
28. Gil M, Barnadas A, Cirera L, et al. Exemestane as neoadjuvant treatment in patients > 65 years with T > 3 cm; preliminary results of a multicenter Spanish phase II trial. Breast Cancer Res Treat 2002; 76(suppl 1):s77 (Abstract #272).
29. Milla-Santos A, Milla L, Rallo L, et al. Anastrozole as neoadjuvant therapy for hormone-dependent locally advanced breast cancer in postmenopausal patients. Proc Am Soc Clin Oncol 2002; 21(suppl 1):40a (Abstract #156).
30. Wagnerova M, Andrasina I, Sokol L, et al. Our first experience with neoadjuvant treatment of postmenopausal locally advanced breast cancer patients with letrozole. Proc Am Soc Clin Oncol 2003; 22:80 (Abstract #319).
31. Milla-Santos A, Milla L, Calvo N, et al. Anastrozole is an effective neoadjuvant therapy for patients with hormone-dependent locally advanced breast cancer irrespective of cerbB2. Proc Am Soc Clin Oncol 2003; 22:39 (Abstract #154).
32. Sanchez R, Duarte C, Perry F, et al. Open-study evaluation of neoadjuvant hormonal therapy in premenopausal patients with advanced breast cancer. Proc Am Soc Clin Oncol 2002; 21:56b (Abstract #2034).
33. Gil MJ, Barnadas A, Cirera L, et al. Primary hormonal therapy with exemestane in patients with breast tumors > 3 cm in diameter: results of a Spanish multicenter phase II trial. Proc Am Soc Clin Oncol 2004; 22:27 (Abstract #603).
34. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12:1527-1532.
35. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23:5108-5116.
36. Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: more questions than answers. J Clin Oncol 2005; 23:4842-4844.
37. Cataliotti L, Buzdar A, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor positive breast cancer (PROACT). Cancer 2006; 106:2095-2103.
38. Semiglazov V, Semiglazov VV, Ivanov VG, et al. Anastrozole vs tamoxifen vs combination as neoadjuvant endocrine therapy of postmenopausal breast cancer patients. Proc Am Soc Clin Oncol 2003; 22:880 (Abstract #3538).
39. Semiglazov V, Semiglazov VV, Ivanov VG, et al. Neoadjuvant endocrine therapy: exemestane vs tamoxifen in postmenopausal ER + breast cancer patients (T1-4 N1-2 MO). Breast Cancer Res Treat 2003; 82(suppl 1):s22 (Abstract #111).
40. Semiglazov VF, Ivanov VG, Semiglazov VV, et al. Neoadjuvant endocrine therapy vs chemotherapy for postmenopausal ER positive breast cancer patients. Breast Cancer Res Treat 2004; 88(suppl 1): s106 (Abstract #2090).
41. Polychronis A, Sinnett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomized trial. Lancet Oncol 2005; 6:383-391.
42. Dowsett M, Smith I, Skene A, et al. Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer (Study 223). Proc Am Soc Clin Oncol 2006; 24:6s (Abstract #515).
43. Janus A, Robak T, Smolewski P. The mammalian target of rapamycin (mTOR) kinase pahway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005; 10:479-498.
44. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11:5319-5328.
45. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11:155-168.
46. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808-3816.
47. Tovey S, Dunne B, Witton CJ, et al. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005; 11:4835-4842.
48. Dowsett M, Ebbs SR, Dixon M, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 2005; 23:2477-2492.
49. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003; 63:6523-6531.
50. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001; 61:8452-8458.
51. Mouridson H, Gershavovitch M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-2606.
52. Nabholtz JM, Buzdar A, Pollak W, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18:3758-3767.
53. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen and Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 2000; 18:3748-3757.
54. Howell A, Cuzik J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
55. Hayashi S. Prediction of hormone sensitivity by DNA microarray. Biomed Pharmacother 2004; 58:1-9.